Insect-Cell Neurotropic AAV Capsid Expression with VP1 Initiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Insect cell-derived AAV vectors, particularly AAV9 and AAV10rh, exhibit reduced potency compared to their mammalian cell-derived counterparts, necessitating improved production methods to enhance their CNS tropism and transduction efficiency.

Innovation Solution

A nucleic acid construct with a baculoviral polH promoter operably linked to an mRNA encoding AAV VP1, VP2, and VP3 capsid proteins, utilizing an ACG codon as a suboptimal VP1 translation initiation codon and a nucleotide sequence with high sequence identity to positions 4-42 of SEQ ID NO: 1, ensures efficient production of AAV vectors in insect cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If AAV vectors are produced in insect cells using conventional methods, then production scalability and cost savings are improved, but transduction efficiency and biological potency deteriorate

Engineering Contradiction:

Improveproduction scalabilityVSAvoidtransduction efficiency

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent modifies the translation initiation parameters by replacing the canonical AUG start codon with non-canonical codons (CGG, CGA, AGG, AGA) at specific positions in the VP1, VP2, and VP3 coding sequences. This parameter change in the genetic code allows insect cells to produce capsid proteins with correct stoichiometry, thereby improving transduction efficiency while maintaining the scalability advantages of insect cell production systems.

Inventive Principle:

Principle #35Parameter changes

2Ease of manufacture

If ACG initiation codon is used for VP1 in insect cells, then leaky ribosome scanning is induced for AAV2 capsids, but potency is reduced for other serotypes due to insufficient VP1

Engineering Contradiction:

Improveexpression mechanismVSAvoidvector potency

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the translation initiation parameter by using non-canonical codons (CGG, CGA, AGG, AGA) instead of ACG or AUG at the VP1 start position. This modification corrects the stoichiometry of capsid protein expression across different AAV serotypes, ensuring sufficient VP1 production and maintaining vector potency while still utilizing insect cell expression systems.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent combines multiple non-canonical initiation codons (CGG, CGA, AGG, AGA) as alternative start signals for VP1 translation in insect cells. This merging of multiple codon options provides a robust expression mechanism that overcomes the limitations of single codon approaches and ensures consistent capsid protein production across different AAV serotypes.

Inventive Principle:

Principle #5Merging (Combining)

3Productivity

If VP1, VP2, and VP3 are expressed from a single ORF with canonical AUG start codon, then translation efficiency is improved, but incorrect stoichiometry results in reduced biological activity

Engineering Contradiction:

Improvetranslation efficiencyVSAvoidcapsid protein stoichiometry

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent modifies the translation initiation parameter within the single ORF expression strategy by replacing the canonical AUG start codon with non-canonical codons (CGG, CGA, AGG, AGA) at the VP1 position. This parameter change maintains the simplicity of single ORF expression while correcting the stoichiometry of capsid protein production, thereby achieving both high translation efficiency and correct protein ratios for optimal biological activity.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method produces AAV vectors with in vivo potency at least 1.5 times higher than those produced in mammalian cells, maintaining comparable in vitro potency and overcoming previous inefficiencies in insect cell-based systems.

Implementation Method 1

A nucleic acid construct with a baculoviral polH promoter operably linked to an mRNA encoding AAV VP1, VP2, and VP3 capsid proteins

Methodology Applied

Scientific EffectTranscription:

Implementation Method 2

utilizing an ACG codon as a suboptimal VP1 translation initiation codon

Methodology Applied

Scientific EffectTranslation:

Data Source

PatentUS20250297278A1Insect cell-produced high potency AAV vectors with CNS-tropism

Publication Date: 2025.09.25 UNIQURE BIOPHARMA BV

AI summary

The present invention pertains to nucleic acid constructs for expression of capsid protein of neurotropic AAV vectors in insect cells that allow the manufacture of such AAV vectors with improved potency. The invention further elates to insect cells comprising such constructs and method wherein the insect are used for the production neurotropic AAV vectors with high potency.